We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Global Analyzer Market to Reach USD 16.0 Billion by 2025

By LabMedica International staff writers
Posted on 31 Mar 2017
The global market for clinical chemistry analyzers is expected to reach USD 16.0 billion by 2025, driven by their increased adoption due to the growing prevalence of chronic diseases, fueled further by an increasing geriatric and bariatric population, which is highly susceptible to chronic diseases. More...
The resulting high sample volume requiring high capability analyzing devices will drive the growth of the global clinical chemistry analyzers market, going forward.

These are the latest findings of Grand View Research, Inc., a market research and consulting company.

The increasing prevalence of chronic diseases, such as diabetes, is one of the key growth drivers of the global clinical chemistry analyzers market, as companies are producing advanced analyzers on a large scale to aid diagnosis. Moreover, technological innovations in clinical chemistry analyzers have led to early disease detection and specialized diagnosis in oncology, gynecology, & endocrinology and enabled testing on a larger scale.

Advancements such as advanced modeling & parameter estimation, better resolution, improved pattern recognition, computer-assisted interpretation, and artificial intelligence are providing various benefits, including automatic data acquisition, greater process control allowing real-time automation, efficient parameter monitoring, and automatic variable adjustment.

In terms of products, reagents accounted for the largest share in 2015 due to the wide array of reagents available in the market for meeting different requirements of clinicians. In terms of tests, Basic Metabolic Panel (BMP) held the largest share in 2015, on account of the growing prevalence of lifestyle-induced diseases, such as obesity and other metabolic abnormalities, as well as the rising importance and awareness of point-of-care testing. Based on end-use, hospitals dominated the segment in 2016, owing to high patient volume, frequent readmissions, large sample volumes, and increasing government initiatives to promote efficient diagnostic facilities for generating quick results and improving overall efficiency. Geographically, North America held the highest share of the global clinical chemistry analyzers market in 2016, due to supportive government initiatives and high implementation of practice guidelines released by healthcare organizations in the region.

Technologically advanced clinical chemistry analyzers can analyze a wide range of samples and generate immediate results, thus creating potential for their application in intensive care unit, outpatient clinics, and emergency and surgical wards in future. These benefits are expected to significantly increase physician preference for clinical chemistry analyzers, thus creating the potential for high growth opportunities in the market, going forward.

The huge demand for clinical chemistry analyzers has also resulted in an unprecedented growth of new market entrants, leading to intense competition. The key players in the clinical chemistry analyzers market are extensively undertaking new and advanced product development activities, collaborative strategies, and mergers & acquisitions, resulting in significant market growth.

Going forward, the Asia Pacific clinical chemistry analyzers market is expected to record an exponential growth due to increased outsourcing by instrument manufacturers to countries, such as India and China, located in the region. Additionally, high R&D investments by global players and unexplored opportunities available in Asia Pacific will also be among the key growth drivers of the clinical chemistry analyzers market in the region.


Gold Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Homocysteine Quality Control
Liquichek Homocysteine Control
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Whole-genome sequencing enables broader detection of DNA repair defects to guide PARP inhibitor cancer therapy (Photo courtesy of Illumina)

Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment

Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more

Pathology

view channel
Image: AI models combined with DOCI can classify thyroid cancer subtypes (Photo courtesy of T. Vasse et al., doi 10.1117/1.BIOS.3.1.015001)

AI-Powered Label-Free Optical Imaging Accurately Identifies Thyroid Cancer During Surgery

Thyroid cancer is the most common endocrine cancer, and its rising detection rates have increased the number of patients undergoing surgery. During tumor removal, surgeons often face uncertainty in distinguishing... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.